US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus U.S. Dividend ETF

30.29

+0.26610.89%

Post-market: 30.290.00000.00%16:10 EDT

Volume:207

Turnover:6K

Market Cap:17.42M

PE:- -

High:30.35

Open:30.35

Low:30.29

Close:30.03

52wk High:30.69

52wk Low:24.79

Shares:575.00K

Float Shares:575.00K

Volume Ratio:1.77

T/O Rate:0.04%

Dividend:0.38

Dividend Rate:1.27%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/VUS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"VUS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VUS\",,,,,undefined,":{"symbol":"VUS","market":"US","secType":"STK","nameCN":"Virtus U.S. Dividend ETF","latestPrice":30.2921,"timestamp":1789156800000,"preClose":30.026,"halted":0,"volume":207,"hourTrading":{"tag":"盘后","latestPrice":30.2921,"preClose":30.2921,"latestTime":"16:10 EDT","volume":6,"amount":181.7526,"timestamp":1789157404968,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.008862319323253232,"floatShares":575004,"shares":575004,"eps":0,"marketStatus":"Post-Mkt","change":0.2661,"latestTime":"09-11 18:34:21 EDT","open":30.35,"high":30.35,"low":30.2921,"amount":6301,"amplitude":0.001928,"askPrice":45.48,"askSize":200,"bidPrice":15.16,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789171200000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":30.026,"sharesOutstanding":625004,"nav":30.198,"aum":17364108.34,"dividendRate":0.012667,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":30.2921,"preClose":30.2921,"latestTime":"16:10 EDT","volume":6,"amount":181.7526,"timestamp":1789157404968,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.766211},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VUS\",,,,,undefined,":{"symbol":"VUS","floatShares":575004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.766211,"shares":575004,"dividePrice":0.3837,"high":30.35,"amplitude":0.001928,"preClose":30.026,"low":30.2921,"week52Low":24.79,"pbRate":"--","week52High":30.6924,"institutionHeld":0,"latestPrice":30.2921,"eps":0,"divideRate":0.012667,"volume":207,"delay":0,"ttmEps":0,"open":30.35,"prevYearClose":25.2797,"prevWeekClose":30.5521,"prevMonthClose":30.2009,"prevQuarterClose":29.8174,"fiveDayClose":30.4704,"twentyDayClose":30.6042,"sixtyDayClose":30.1104},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VUS\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"VUS","amount":0.164,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Virtus U.S. Dividend ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-29","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-29"},{"date":"2026-03-20","symbol":"VUS","amount":0.2199,"announcedDate":"2026-03-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-20","defaultRemindTime":1774013400000,"name":"Virtus U.S. Dividend ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-20","currency":"USD","dateTimestamp":1773979200000,"payDate":"2026-03-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VUS\",market:\"US\",,,undefined,":[{"executeDate":"2026-03-20","recordDate":"2026-03-20","paymentDate":"2026-03-27","value":0.2199,"currency":"USD"},{"executeDate":"2026-06-22","recordDate":"2026-06-22","paymentDate":"2026-06-29","value":0.164,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VUS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VUS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666530593","title":"Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530593","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666530593?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:00","pubTimestamp":1789041600,"startTime":"0","endTime":"0","summary":"-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359459/0/en/rhythm-pharmaceuticals-announces-new-data-presentations-at-the-european-society-for-paediatric-endocrinology-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VAI","EPV","BK4166","VUS","AVP","EC","BK4201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661627957","title":"Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627957","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627957?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572800,"startTime":"0","endTime":"0","summary":"-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --  BOSTON, Aug.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349657/0/en/rhythm-pharmaceuticals-announces-mhlw-approval-of-imcivree-setmelanotide-for-patients-with-acquired-hypothalamic-obesity-ho-in-japan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4157","VUS","AVP","BK4201","BMI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848797","title":"Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848797","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848797?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:00","pubTimestamp":1786968000,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3346041/0/en/rhythm-pharmaceuticals-announces-appointment-of-manher-aj-joshi-as-chief-medical-officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","EC","BK4534","BK4566","NKE","STYL","LU0310800379.SGD","LU0889566641.SGD","LU0786609619.USD","LU1267930227.SGD","LU1267930813.SGD","VUS","LU0128525929.USD","BK4588","LU0310800965.SGD","LU0029864427.USD","BK4585","BK4561","LU1267930573.SGD","LU1303367103.USD","BK4558","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","LU0792757196.USD","LU0823411888.USD","LU2098885051.SGD","LU0052756011.USD","BK4146","BK4581","BK4201","LU0708994859.HKD","AVP","LU0128525689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658902819","title":"Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658902819","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658902819?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"-- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --BOSTON, Aug.  11, 2026  (GLOBE NEWSWIRE) -- Rhythm Phar","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342640/0/en/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-receives-expanded-marketing-authorization-in-the-united-kingdom-for-treatment-of-obesity-and-control-of-hunger-in-patients-w.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","BK4157","EC","BMI","AVP","BK4211","UBCP","VUS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VUS\",params:#limit:6,delay:false,,,undefined,":[]}}